A detailed history of Gsa Capital Partners LLP transactions in Evolus, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 120,964 shares of EOLS stock, worth $1.21 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
120,964
Previous 27,788 335.31%
Holding current value
$1.21 Million
Previous $301,000 551.16%
% of portfolio
0.15%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$10.66 - $17.48 $993,256 - $1.63 Million
93,176 Added 335.31%
120,964 $1.96 Million
Q2 2024

Aug 15, 2024

BUY
$10.45 - $13.76 $290,384 - $382,362
27,788 New
27,788 $301,000
Q3 2023

Nov 15, 2023

SELL
$7.15 - $10.2 $624,566 - $890,990
-87,352 Reduced 88.79%
11,026 $100,000
Q2 2023

Aug 14, 2023

BUY
$7.23 - $10.52 $711,272 - $1.03 Million
98,378 New
98,378 $715,000
Q4 2022

Feb 13, 2023

BUY
$6.52 - $8.95 $47,850 - $65,684
7,339 Added 59.52%
19,669 $148,000
Q3 2022

Nov 14, 2022

BUY
$7.76 - $13.72 $95,680 - $169,167
12,330 New
12,330 $99,000
Q1 2020

May 12, 2020

SELL
$3.53 - $12.21 $55,424 - $191,709
-15,701 Closed
0 $0
Q4 2019

Feb 12, 2020

BUY
$11.58 - $17.37 $36,002 - $54,003
3,109 Added 24.69%
15,701 $191,000
Q3 2019

Nov 12, 2019

SELL
$13.91 - $19.87 $81,721 - $116,736
-5,875 Reduced 31.81%
12,592 $197,000
Q2 2019

Aug 06, 2019

BUY
$13.19 - $28.36 $17,081 - $36,726
1,295 Added 7.54%
18,467 $270,000
Q1 2019

May 15, 2019

BUY
$12.43 - $28.91 $213,447 - $496,442
17,172 New
17,172 $388,000
Q4 2018

Feb 12, 2019

SELL
$10.57 - $19.29 $376,979 - $687,977
-35,665 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$17.31 - $29.82 $617,361 - $1.06 Million
35,665 New
35,665 $664,000

Others Institutions Holding EOLS

About Evolus, Inc.


  • Ticker EOLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 56,094,800
  • Market Cap $561M
  • Description
  • Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...
More about EOLS
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.